Clinical characteristics of 58 de novo CN-AML samples in the test cohort
| Characteristic . | Unit of measure . | Value . |
|---|---|---|
| Age at diagnosis | Y (range) | 47 (18-68) |
| Sex | n female | 37 (64%) |
| FAB class | M0 | 5 |
| M1 | 24 | |
| M2 | 8 | |
| M4 | 10 | |
| M5 | 9 | |
| M6 | 2 | |
| Blast percentage at diagnosis | (range) | 67% (20-98) |
| Leukocyte count at diagnosis | E9/L (range) | 66 (0.9-312) |
| NPM1 mutation | n/analyzed | 22/58 (55%) |
| FLT3-ITD | n/analyzed | 21/58 (36%) |
| FLT3-TKD | n/analyzed | 12/58 (21%) |
| CEBPA mutation | n/analyzed | 6/58 (10%) |
| IDH1 mutation | n/analyzed | 14/57 (25%) |
| IDH2 mutation | n/analyzed | 12/57 (21%) |
| Any IDH mutation | n/analyzed | 24/57 (42%) |
| DNMT3A mutation | n/analyzed | 13/47 (28%) |
| CR after 1 induction | n | 23 (39%) |
| Allogeneic SCT | n | 24 (41%) |
| Alive at 2 years | n/eligible | 23/51 (45%) |
| Characteristic . | Unit of measure . | Value . |
|---|---|---|
| Age at diagnosis | Y (range) | 47 (18-68) |
| Sex | n female | 37 (64%) |
| FAB class | M0 | 5 |
| M1 | 24 | |
| M2 | 8 | |
| M4 | 10 | |
| M5 | 9 | |
| M6 | 2 | |
| Blast percentage at diagnosis | (range) | 67% (20-98) |
| Leukocyte count at diagnosis | E9/L (range) | 66 (0.9-312) |
| NPM1 mutation | n/analyzed | 22/58 (55%) |
| FLT3-ITD | n/analyzed | 21/58 (36%) |
| FLT3-TKD | n/analyzed | 12/58 (21%) |
| CEBPA mutation | n/analyzed | 6/58 (10%) |
| IDH1 mutation | n/analyzed | 14/57 (25%) |
| IDH2 mutation | n/analyzed | 12/57 (21%) |
| Any IDH mutation | n/analyzed | 24/57 (42%) |
| DNMT3A mutation | n/analyzed | 13/47 (28%) |
| CR after 1 induction | n | 23 (39%) |
| Allogeneic SCT | n | 24 (41%) |
| Alive at 2 years | n/eligible | 23/51 (45%) |
FAB indicates French-American-British; and SCT, stem cell transplantation.